Immunocore Holdings Investor Relations Material
Latest events
Q2 2025
Immunocore Holdings
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immunocore Holdings plc
Access all reports
Immunocore Holdings plc is a commercial-stage biotechnology company focused on the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune diseases. Utilizing its proprietary T cell receptor (TCR) technology, the company aims to create transformative medicines to address unmet medical needs. Among its notable products is KIMMTRAK, designed for the treatment of patients with unresectable or metastatic uveal melanoma. Immunocore is headquartered in Abingdon, the United Kingdom, and is listed on the NASDAQ stock exchange under the ticker symbol IMCR.
Key slides for Immunocore Holdings plc
Q2 2024
Immunocore Holdings plc
Q2 2025
Immunocore Holdings plc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
IMCR
Country
🇺🇸 United States